Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of
low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose
corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA
nephropathy with stage 3 or 4 chronic kidney disease.